Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Ruxolitinib in Metastatic Triple Negative Breast Cancer
NCT06008275Phase 1Recruiting
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Sep 2024
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neratinib and ruxolitinib in triple-negative breast cancer (TNBC), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Objective Response Rate at 18 months. Started Sep 2024; status: recruiting.
02
Drugs
neratinibruxolitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06008275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008275.